Gene therapy for inherited blindness passes early safety check
NCT ID NCT02064569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a gene therapy called GS010 in 19 adults with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that causes rapid vision loss. The main goal was to see if the treatment is safe and tolerable at different doses. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to stop or slow vision loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIC du CHNO DES QUINZE-VINGTS
Paris, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could stem cells restore sight in damaged eyes?
- Gene therapy shows promise for rare eye disease that causes blindness
- New study tracks daily life impact of rare eye disease
- New laser device could revolutionize eye disease detection
- Can a simple blood test predict blindness before it starts?
- Gene therapy shows promise in Long-Term study for rare blindness